Evangelia Kokalaki

Title: Evangelia Kokalaki: Innovator in Chimeric Antigen Receptors

Introduction

Evangelia Kokalaki is a prominent inventor based in London, GB. She has made significant contributions to the field of biotechnology, particularly in the development of chimeric antigen receptors (CARs). With a total of three patents to her name, her work is paving the way for advancements in targeted therapies.

Latest Patents

Among her latest patents, Evangelia has developed a chimeric antigen receptor that binds to target antigens with bulky extracellular domains. This innovative CAR comprises a Fab antigen binding domain, which enhances its effectiveness. The patent also includes nucleic acid sequences and constructs that encode such a CAR, as well as cells that express this CAR and their therapeutic applications.

Career Highlights

Evangelia Kokalaki is currently associated with Autolus Limited, a company known for its cutting-edge research in cell and gene therapies. Her work at Autolus has been instrumental in advancing the understanding and application of CAR technology in treating various diseases.

Collaborations

Evangelia collaborates with notable colleagues, including Shimobi Onuoha and Martin Pulé. These partnerships enhance the innovative environment at Autolus Limited and contribute to the success of their research initiatives.

Conclusion

Evangelia Kokalaki is a trailblazer in the field of chimeric antigen receptors, with her patents reflecting her commitment to advancing medical science. Her contributions are vital for the future of targeted therapies, and her work continues to inspire innovation in biotechnology.